Pathway analysis confirmed increased immune activation in CAs compared with AAs (Fig. 1B), with patients with adenocarcinoma showing increased immune activation pathways including Toll-like receptor pathways and IL17A signaling in CAs compared with AAs. Here, IL17A is linked to adenocarcinoma.